Literature DB >> 8261577

Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.

M Barberi-Heyob1, G Griffon, J L Merlin, B Weber.   

Abstract

The present study was designed to analyze the growth-inhibitory effects of the combination of fluorouracil (FUra), cisplatin (CDDP), and dipyridamole (DP). These toxic effects were assessed on the human breast-carcinoma cell line MCF-7 using the MTT (tetrazolium bromide) assay in 96-well culture dishes. Data were analyzed using the median-effect principle. The drug combinations tested included FUra concentrations ranging from 0.8 to 800 nmol/l, CDDP concentrations of 0.3-30 mumol/l, and DP concentrations of 2-200 mumol/l. A total of 189 different experimental conditions were tested, including different sequences of administration, with being DP applied before, simultaneously with, or after the two antitumor drugs. Synergistic cytotoxic interactions were found between FUra and CDDP, FUra and DP, and CDDP and DP as well as when the three drugs were combined. The sequence of exposure did not influence the growth-inhibitory activity of the combination FUra-CDDP but altered the effect of combinations of either FUra or CDDP with DP, since at lower concentrations the effect shifted from synergism to antagonism when DP was added simultaneously with CDDP and after the two antitumor drugs. However, the interaction was shown to be truly synergistic by median-effect analysis when the two antitumor drugs were simultaneously associated, with no change in the synergistic effect being observed for the three DP administration sequences.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261577     DOI: 10.1007/bf00685336

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Cellular pharmacologic strategies for overcoming drug resistance: potential applications to regional therapy.

Authors:  S B Howell; S Isonishi; R D Christen; P A Andrews; S Mann
Journal:  Eur J Surg Suppl       Date:  1991-05

2.  Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients.

Authors:  T C Chan; G L Coppoc; S Zimm; S Cleary; S B Howell
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

3.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

4.  Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy.

Authors:  M Perloff; R D Hart; J F Holland
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

5.  Mitomycin C and vinblastine chemotherapy for advanced breast cancer.

Authors:  P H Konits; J Aisner; D A van Echo; K Lichtenfeld; P H Wiernik
Journal:  Cancer       Date:  1981-09-15       Impact factor: 6.860

6.  Intraperitoneal injection of dipyridamole increases the life span of tumor bearing mice treated with fluorouracil.

Authors:  M Barberl-Heyob; J L Merlin; B Weber
Journal:  In Vivo       Date:  1992 Sep-Oct       Impact factor: 2.155

7.  The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.

Authors:  T E Keane; G L Rosner; J R Gingrich; S H Poulton; P J Walther
Journal:  J Urol       Date:  1991-11       Impact factor: 7.450

8.  Sensitive determination of free and plasma protein-bound dipyridamole by high-performance liquid chromatography.

Authors:  M Barberi; J L Merlin; B Weber
Journal:  J Chromatogr       Date:  1991-04-19

9.  Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

Authors:  S Shionoya; Y Lu; K J Scanlon
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

10.  Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.

Authors:  J L Grem; P H Fischer
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  4 in total

1.  Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells.

Authors:  Qing Li; Yan Shu
Journal:  Pharm Res       Date:  2013-07-25       Impact factor: 4.200

2.  In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.

Authors:  O Bruserud; I Nesthus; G Pawelec
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.

Authors:  J F Mirjolet; M Barberi-Heyob; C Didelot; J P Peyrat; J Abecassis; R Millon; J L Merlin
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

4.  Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity.

Authors:  J F Mirjolet; M Barberi-Heyob; J L Merlin; S Marchal; M C Etienne; G Milano; P Bey
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.